{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=5",
    "query": {
      "intervention": "Immune checkpoint inhibitor",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 371,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T10:23:21.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07898124",
      "title": "TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "HNSCC",
        "Neoplasm Recurrence, Local",
        "Recurrent Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TMV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Toripalimab-tpzi",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Metaclipse Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-01",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07898124"
    },
    {
      "nct_id": "NCT04501094",
      "title": "A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Bintrafusp alfa (M7824)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-10-26",
      "completion_date": "2021-10-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501094"
    },
    {
      "nct_id": "NCT03878979",
      "title": "Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Cancer",
        "Head and Neck Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Nivolumab 480mg and surgical resection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-07-08",
      "completion_date": "2023-10-17",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03878979"
    },
    {
      "nct_id": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "PF-07985045",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluorouracil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Oxaliplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Leucovorin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bevacizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sasanlimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PF-07284892",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-12-10",
      "completion_date": "2026-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 12,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06704724"
    },
    {
      "nct_id": "NCT04387461",
      "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CG0070",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "n-dodecyl-B-D-maltoside",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2020-12-08",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Orange, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387461"
    },
    {
      "nct_id": "NCT04892043",
      "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SQZ-AAC-HPV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SQZ Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-08-19",
      "completion_date": "2023-11-02",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 6,
      "location_summary": "Duarte, California • La Jolla, California • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04892043"
    },
    {
      "nct_id": "NCT03041311",
      "title": "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2017-06-29",
      "completion_date": "2020-10-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 23,
      "location_summary": "Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041311"
    },
    {
      "nct_id": "NCT07908329",
      "title": "Intradermal Influenza Vaccination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Vaccine Reaction"
      ],
      "interventions": [
        {
          "name": "MicronJet",
          "type": "DEVICE"
        },
        {
          "name": "Fluzone® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® High Dose Quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2026-10-01",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07908329"
    },
    {
      "nct_id": "NCT05812274",
      "title": "Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-05-31",
      "completion_date": "2025-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812274"
    },
    {
      "nct_id": "NCT04290546",
      "title": "CIML NK Cell in Head & Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck",
        "Recurrent Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Interleukin-15 Superagonist (N-803)",
          "type": "DRUG"
        },
        {
          "name": "CIML NK cell Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-07-20",
      "completion_date": "2024-12-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-15T10:23:21.881Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04290546"
    }
  ]
}